Honasa Consumer Ltd has announced plans to acquire a 58% controlling stake in Fluence Pharma, marking its formal entry into the science-backed nutraceuticals market.
The deal values the target at approximately ₹135 crore on an enterprise value basis, with the initial acquisition structured as a secondary share purchase.
After securing the initial majority stake, Honasa intends to acquire the remaining 42% of Fluence Pharma in two tranches over the next five to seven years.
The company disclosed the transaction in a filing to the Bombay Stock Exchange on Tuesday.
The acquisition strategy involves a phased approach to full ownership.
After securing the initial majority stake, Honasa intends to acquire the remaining 42% of Fluence Pharma in two tranches over the next five to seven years.
This long-term structure suggests a deliberate integration plan, allowing the beauty and personal care conglomerate to absorb the nutraceutical business gradually while managing capital allocation.